RT Journal Article
SR Electronic
T1 The influence of APOE status on cognitive decline
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.05.23.23290400
DO 10.1101/2023.05.23.23290400
A1 Morrison, Cassandra
A1 Oliver, Michael D.
A1 Berry, Virginia
A1 Kamal, Farooq
A1 Dadar, Mahsa
YR 2023
UL http://medrxiv.org/content/early/2023/05/28/2023.05.23.23290400.abstract
AB INTRODUCTION Apolipoprotein (APOE) ε4 and subjective cognitive decline (SCD) increase risk of Alzheimer’s disease. However, few studies have examined the relationship between SCD and APOE, especially using longitudinal data. The current study examined whether APOE is associated with the rate of cognitive change in SCD.METHODS Linear mixed effects models examined the relationship between APOE status and cognitive change in older adults with SCD (SCD), normal controls (NC), and people with mild cognitive impairment (MCI).RESULTS The presence of at least one ε2 allele in SCD and MCI results in cognitive change rates similar to a NC with the ε3ε3 genotype. Older SCD-ε4 individuals exhibited increased cognitive decline compared to all groups, including NC-ε4 and MCI-ε4.DISCUSSION People with SCD with at least one ε4 allele will experience increased cognitive decline compared to cognitively healthy older adults and people with MCI. These findings have important implications for treatments and interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Morrison is supported by a postdoctoral fellowship from Canadian Institutes of Health Research, Funding Reference Number: MFE-176608. Dr. Kamal is supported by the Quebec Bioimaging Network and Fonds de Recherche du Quebec (FRQS) postdoctoral scholarships. Dr. Dadar reports receiving research funding from the Healthy Brains for Healthy Lives (HBHL), Alzheimer Society Research Program (ASRP), Natural Sciences and Engineering Research Council of Canada (NSERC), Fonds de Recherche du Quebec (FRQS), and Douglas Research Centre (DRC). The RADC/ RUSH cohort studies are supported by the National Institutes of Health, National Institute on Aging (R01 AG17917, R01 AG22018, P30 AG10161, and P30 AG72975). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used (or will use) ONLY openly available human data that were originally located at: https://www.radc.rush.edu/.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://www.radc.rush.edu/. https://www.radc.rush.edu/.